Deregulation of p53-associated metabolic activities has been linked to tumor development, as well as to other pathophysiological conditions including aging, obesity, type 2 diabetes, and liver disease3–7. This evidence concerns the gene TP53 and obesity due to melanocortin 4 receptor deficiency.